As filed with the Securities and Exchange Commission on August 7, 2019.

Registration No. 333-          

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM S-8

 

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

 

Momenta Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

 

04-3561634

(State or other jurisdiction of incorporation or
organization)

 

(I.R.S. Employer Identification No.)

 

301 Binney Street
Cambridge, Massachusetts

 


02142

(Address of Principal Executive Offices)

 

(Zip Code)

 

Momenta Pharmaceuticals, Inc. 2013 Incentive Award Plan

(Full title of the plan)

 

Alejandra Carvajal

Momenta Pharmaceuticals, Inc.

301 Binney Street

Cambridge, Massachusetts 02142

(Name and address of agent for service)

 

(617) 491-9700

(Telephone number, including area code, of agent for service)

 

Copy to:

 

Peter N. Handrinos

Latham & Watkins LLP

200 Clarendon Street, 27 th  Floor

Boston, Massachusetts 02116

(617) 948-6000

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” or “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer  x

Accelerated filer  o

Non-accelerated filer  o

Smaller reporting company  o

 

Emerging growth company  o

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  o

 

CALCULATION OF REGISTRATION FEE

 

 

 

 

 

 

 

 

 

 

Title of securities to be registered

 

Amount
to be
registered(1)

 

Proposed
maximum
offering price
per share(3)

 

Proposed
maximum
aggregate
offering price(3)

 

Amount of
registration
fee

 

Common stock, par value $0.0001 per share

 

4,000,000

(2)

$

11.30

 

$

45,200,000

 

$

5,478.24

 

 

 

 

 

 

 

 

 

 

 

 

(1)          In accordance with Rule 416 under the Securities Act of 1933, as amended, this registration statement shall be deemed to cover any additional securities that may from time to time be offered or issued to prevent dilution resulting from stock splits, stock dividends or similar transactions.

(2)          Consists of an additional 4,000,000 shares issuable under the Momenta Pharmaceuticals, Inc. 2013 Incentive Award Plan, as amended and restated (the “2013 Plan”).

(3)          Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act of 1933, as amended, and based upon the average of the high and low prices of the Registrant’s common stock, par value $0.0001 per share (the “Common Stock”), as reported on The Nasdaq Global Select Market on August 5, 2019.

 

 

 


 

EXPLANATORY NOTE

 

This Registration Statement on Form S-8 is being filed for the purpose of registering an additional 4,000,000 shares of the Registrant’s Common Stock to be issued under the 2013 Plan, for which Registration Statements on Form S-8 of the Registrant relating to such employee benefit plan are effective.

 

STATEMENT OF INCORPORATION BY REFERENCE

 

This Registration Statement on Form S-8 hereby incorporates by reference the contents of the Registration Statements on Form S-8 (File Nos. 333-226759 , 333-219764 , 333-212991 , 333-206112 , 333-197582 and 333-190394 ).

 

Item 8.  Exhibits.

 

Exhibit
Number

 

Description

 

 

 

4.1(1)

 

Third Amended and Restated Certificate of Incorporation of the Registrant

 

 

 

4.1(2)

 

Certificate of Amendment to Third Amended and Restated Certificate of Incorporation of the Registrant

 

 

 

4.2(3)

 

Certificate of Designations of Series A Junior Participating Preferred Stock, dated November 8, 2005

 

 

 

4.3(4)

 

Fourth Amended and Restated By-laws of the Registrant

 

 

 

4.4(5)

 

Specimen certificate evidencing shares of common stock of the Registrant

 

 

 

5.1

 

Opinion of Latham & Watkins LLP

 

 

 

23.1

 

Consent of Ernst & Young LLP

 

 

 

23.2

 

Consent of Latham & Watkins LLP (included in Exhibit 5.1)

 

 

 

24.1

 

Power of Attorney (included on signature page)

 

 

 

99.1(6)

 

Momenta Pharmaceuticals, Inc. 2013 Incentive Award Plan (as amended and restated)

 


(1)           Filed as Exhibit 3.1 to the Registrant’s Registration Statement on Form S-3 filed on April 30, 2013 (File No. 333-188227) and incorporated herein by reference.

 

(2)           Filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on January 30, 2019 (File No. 000-50797) and incorporated herein by reference.

 

2


 

(3)           Filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on November 8, 2005 (File No. 000-50797) and incorporated herein by reference.

 

(4)           Filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on March 17, 2017 (File No. 000-50797) and incorporated herein by reference.

 

(5)           Filed as Exhibit 4.1 to Amendment No. 4 to the Registrant’s Registration Statement on Form S-1 filed on June 15, 2004 (File No. 333-113522) and incorporated herein by reference.

 

(6)           Filed as Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q filed on August 7, 2019 (File No. 000-50797) and incorporated herein by reference.

 

3


 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts, on August 7, 2019.

 

 

MOMENTA PHARMACEUTICALS, INC.

 

 

 

 

 

By:

/s/ Craig A. Wheeler

 

Name:

Craig A. Wheeler

 

Title:

President and Chief Executive Officer

 

POWER OF ATTORNEY AND SIGNATURES

 

Each person whose signature appears below hereby constitutes and appoints Craig A. Wheeler and Alejandra Carvajal, and each of them singly, with full power to act without the other, such person’s true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign this registration statement and any and all amendments, including post-effective amendments to this registration statement, and to file the same, with exhibits and schedules thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary or desirable to be done in connection therewith as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitute or substitutes may lawfully do or cause to be done by virtue hereof.

 

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the date indicated.

 

4


 

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the date indicated.

 

Signature

 

Title

 

Date

 

 

 

 

 

/s/ Craig A. Wheeler

 

President, Chief Executive Officer and Director

 

August 7, 2019

Craig A. Wheeler

 

(Principal Executive, Financial and Accounting Officer)

 

 

 

 

 

 

 

/s/ Michelle Robertson

 

Senior Vice President and Chief Financial Officer

 

August 7, 2019

Michelle Robertson

 

(Principal Financial and Accounting Officer)

 

 

 

 

 

 

 

/s/ Bruce L. Downey

 

Chairman of the Board and Director

 

August 7, 2019

Bruce L. Downey

 

 

 

 

 

 

 

 

 

/s/ Corey N. Fishman

 

Director

 

August 7, 2019

Corey N. Fishman

 

 

 

 

 

 

 

 

 

/s/ Georges Gemayel

 

Director

 

August 7, 2019

Georges Gemayel

 

 

 

 

 

 

 

 

 

/s/ Steven C. Gilman

 

Director

 

August 7, 2019

Steven C. Gilman

 

 

 

 

 

 

 

 

 

/s/ Jose-Carlos Gutiérrez-Ramos

 

Director

 

August 7, 2019

Jose-Carlos Gutiérrez-Ramos

 

 

 

 

 

 

 

 

 

/s/ Thomas P. Koestler

 

Director

 

August 7, 2019

Thomas P. Koestler

 

 

 

 

 

 

 

 

 

/s/ Elizabeth Stoner

 

Director

 

August 7, 2019

Elizabeth Stoner

 

 

 

 

 

5


Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Momenta Pharmaceuticals Charts.
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Momenta Pharmaceuticals Charts.